A Trial of Finerenone in a Patient with Primary Aldosteronism
Introduction: Primary aldosteronism (PA), a common secondary cause of arterial hypertension, is treated either surgically or pharmacologically with mineralocorticoid receptor antagonists (MRAs). These drugs, while effective, can cause allergic reactions and have side effects, including menstrual cyc...
Saved in:
Main Author: | Sandra Karanović Štambuk (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baxdrostat and finerenone: new aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system inhibitors for the drug treatment of resistant arterial hypertension
by: O. B. Kuzmin, et al.
Published: (2024) -
Administration of finerenone in chronic kidney disease
by: Mohsen Akhavan Sepahi, et al.
Published: (2023) -
Residual Renal Function: A Double-Edged Sword
by: Sandra Karanović Štambuk, et al.
Published: (2024) -
A case of primary aldosteronism
by: Stephanie Zilberman, et al.
Published: (2022) -
Primary Aldosteronism and Pregnancy
by: Tomáš Zelinka, et al.
Published: (2020)